Market Overview

Drug design strategies for anti-virals and combating resistance

Share:

SMi is proud to present their 12th annual conference on Drug Design that will be held on the 18th & 19th February in London. This unique conference will provide an unparalleled opportunity for debate and problem solving of key challenges currently facing the field, allowing attendees to discuss progress in the area and exchange ideas moving forward, ensuring a truly comprehensive treatment of the most important issues.

London, UK (PRWEB UK) 2 November 2012

It will also focus on the latest developments in this fast-paced field and bring together senior representatives from industry and academia to discuss Statistical Issues in CADD, Binding Site Solvent Analysis, Structure-Based Lead Discovery and G-protein-coupled receptors.

SMi is pleased to announce that Andrew Leach, Director of Bimolecular Structure, GlaxoSmithKline has confirmed to speak at the upcoming event.

He will be presenting the keynote address on public-private partnerships under the Innovative Medicines Initiative (IMI). This involves large Pharma, academics and SMEs and an open infrastructure based on semantic technologies for the integration of pharmacological data in the life sciences. He will also look at key challenges in sustainability, provenance, and licensing private data.

KEY TOPICS FOR 2013:

  • Computational approaches in polypharmacology and mode-of-action analysis
  • Applying CADD to protein therapeutics
  • Drug design strategies for anti-virals and combating resistance
  • Developments in water network perturbation in structure-based drug design
  • Discovery of novel inhibitors through structure-based fragment evolution
  • Data integration and developments in public-private partnerships

For more information visit http://www.smi-online.co.uk/2013drugdesign33.asp or alternatively contact Fateja Begum on email fbegum(at)smi-online(dot)co(dot)uk or tel. +44 0207 827 6184.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10083788.htm

View Comments and Join the Discussion!